Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | MMP13 | P45452 | 3/20 | 0.36 |
| ▸ | MMP10 | P09238 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 2/20 | 0.35 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | COMT | P21964 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7206608 | 0.89 | USP5 (0.41) | USP5MMP3MMP2MMP13MMP9 | |
| SCHEMBL7205721 | 0.89 | MMP13 (0.45) | USP5MMP3MMP2MMP13MMP9 | |
| SCHEMBL7201610 | 0.89 | MMP2 (0.47) | USP5MMP3MMP2MMP13MMP9 | |
| SCHEMBL7200489 | 0.88 | USP5 (0.44) | USP5NAMPTMMP2MMP13MMP9 | |
| SCHEMBL7205659 | 0.87 | TP53 (0.41) | NAMPTMMP3MMP2MMP13MMP9 | |
| SCHEMBL7207178 | 0.87 | USP5 (0.43) | USP5MMP3MMP2MMP13MMP10 | |
| SCHEMBL7202573 | 0.85 | MMP13 (0.43) | NAMPTMMP3MMP2MMP13MMP9 | |
| SCHEMBL7201770 | 0.83 | MMP2 (0.44) | MMP3MMP2MMP13MMP9ADAM10 | |
| SCHEMBL7201688 | 0.83 | MMP13 (0.43) | MMP2MMP13ALDH1A1 | |
| SCHEMBL7200985 | 0.82 | MMP13 (0.48) | USP5MMP3MMP2MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6608104-B2 | Antiarthritic agents; anticancer agents | PFIZER INC | 2003-08-19 | — | — | US | disclosed |
| US-20020019534-A1 | Gem substituted hydroxamic acids | PFIZER INC. | 2002-02-14 | — | — | US | disclosed |
| EP-1138680-A1 | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors | Pfizer Products Inc. (US) | 2001-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019534-A1 | Gem substituted hydroxamic acids | MMP14, TOP2A, ADAMTS1 | USP5 1778/4885NAMPT 4299/4885MMP3 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.